ArticleInternational journal of nanomedicine2025
Proteomic Landscape of Small Extracellular Vesicles Derived From Gastric Juice and Identified TFF2 as a Specific Biomarker.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Global research trends in signaling pathways of spasmolytic polypeptide-expressing metaplasia pathogenesis: a bibliometric analysis.Frontiers in oncology · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Small extracellular vesicles (sEVs) derived from gastric juice (GJ) have emerged as potential biomarkers for gastric disease. However, methods for isolating sEVs from GJ (gsEVs) remain underexplored. Methods: This study employed four methods for isolating gsEVs: ultracentrifugation (UC), PEG6000 precipitation combined with UC (PEG-UC), UC combined with size exclusion chromatography (UC-SEC), and ultrafiltration combined with SEC (UF-SEC). The yield and purity of gsEVs isolated by each method were evaluated, and the proteomic profile of gsEVs was examined through label-free quantitative proteomics. Additionally, a series of validation experiments were conducted to identify specific biomarkers for gsEVs. Results: The results revealed that gsEVs isolated using the UC method exhibited the highest purity and the largest number of identified proteins compared to the other methods. Notably, the gastric tissue-specific peptide trefoil factor 2 (TFF2) was highly expressed in gsEVs isolated by all methods, suggesting that TFF2 may serve as a specific biomarker for gsEVs. Validation experiments showed that TFF2 was exclusively present in gsEVs and not in the GJ supernatant after UC. Furthermore, TFF2 was selectively expressed in gsEVs, but not in sEVs derived from other biofluids such as intestinal juice and plasma. The efficiency of TFF2 as a gsEVs biomarker was higher than the commonly used biomarker CD9, CD81, and Syntenin-1. Multi-omics analysis indicated that the functions of gsEVs carrying TFF2 were primarily associated with inflammation and cancer. Conclusion: The UC method is suitable for isolating gsEVs, particularly for mass spectrometry-based proteomic analysis. The small peptide TFF2 may serve as a potential specific biomarker for gsEVs. This study offers new insights for research on sEVs in gastric diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.